PT ITAMA RANORAYA TBK |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 488 IDR | -0.81% |
|
-2.01% | -39.00% |
| Apr. 02 | PT Itama Ranoraya Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | PT Itama Ranoraya Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| Sales 2022 | 754B 45.97M | Sales 2023 | 696B 42.47M | Capitalization | 1,250B 76.25M |
|---|---|---|---|---|---|
| Net income 2022 | 48B 2.93M | Net income 2023 | 5.2B 317K | EV / Sales 2022 | 2.3 x |
| Net Debt 2022 | 43.42B 2.65M | Net Debt 2023 | 149B 9.08M | EV / Sales 2023 | 2.01 x |
| P/E ratio 2022 |
35.2
x | P/E ratio 2023 |
238
x | Employees | 221 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 13.06% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.81% | ||
| 1 week | -2.01% | ||
| Current month | -1.21% | ||
| 1 month | +3.83% | ||
| 3 months | -0.81% | ||
| 6 months | -8.79% | ||
| Current year | -39.00% |
1 week
484.00
505.00
1 month
466.00545.00
Current year
462.00815.00
1 year
436.001 045.00
3 years
436.002 280.00
5 years
350.004 390.00
10 years
350.004 390.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 60 | - | |
| Comptroller/Controller/Auditor | 37 | 20-03-31 | |
Hendry Herman
PRN | Corporate Officer/Principal | 44 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 59 | 21-12-31 | |
| Corporate Secretary | 61 | 18-12-31 | |
Tjandra Aditama
CHM | Chairman | 69 | 20-11-12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 488 | -0.81% | 1,434,100 |
| 24-06-03 | 492 | -0.40% | 1,041,100 |
| 24-05-31 | 494 | -0.40% | 1,507,100 |
| 24-05-30 | 496 | 0.00% | 1,172,600 |
| 24-05-29 | 496 | -0.40% | 4,517,300 |
End-of-day quote INDONESIA S.E., June 03, 2024
More quotes
PT Itama Ranoraya Tbk is an Indonesia-based healthcare company engaged in offering healthcare solutions. The Company's main activity is to operate in the field of wholesale trading of laboratory equipment, pharmaceutical equipment, and medical devices for humans. Its segments include In Vitro Diagnostic (IVD) Product, Sterile Non-Electromedical Medical Equipment, Electromedical Medical Equipment, and Others. Its business segment focuses on IVD, medical imaging, surgical, cardiovascular, hospital supplies, critical care, maternal and neonatal care, and pharmaceuticals, among others. In addition to carrying out its main business activities, the Company also leases office space to PT Neumedik Jaya.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -39.00% | 45.3M | |
| -6.03% | 180B | |
| +1.08% | 109B | |
| -2.19% | 68.93B | |
| -5.98% | 46.41B | |
| +12.31% | 45.43B | |
| +7.38% | 43.26B | |
| +15.98% | 30.05B | |
| +16.10% | 25.19B | |
| -9.57% | 23.19B |
- Stock Market
- Equities
- IRRA Stock
